Technology · NYSE · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated .
WATERS CORP /DE/ (WAT) stock profile, AI quality score, and SEC EDGAR financial data, a Technology sector company. 13F Pro's AI-powered ranking engine scores WAT at 60.4/100 on a 32-signal composite quality model, placing it at rank #853 of 2,960 stocks — the top half of the AI-ranked universe. WAT scores in the top quartile across revenue growth (85.8), earnings quality (82.2), revenue scale (76.9). Areas of concern include profitability (31.7), which score below median versus the broader universe. Shareholder dilution risk is elevated at 43.0/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), WATERS CORP /DE/ reports quarterly revenue of $1.6B, net income of $-136.0M, free cash flow of $153.0M. Top institutional holders of WAT by reported 13-F value include BlackRock, MASSACHUSETTS FINANCIAL SERVICES, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. WAT trades on the NYSE exchange and files with the SEC under CIK 1000697. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate WAT daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for WATERS CORP /DE/ directly from SEC EDGAR.
AI Quality Score
60.4/100
AI Rank
#853
Revenue
$1.6B
Net Income
$-136.0M
Free Cash Flow
$153.0M
| Period | Form | Revenue | Net income | Operating margin |
|---|---|---|---|---|
| FY 2025 | 10-K | $3.2B | $642.6M | 25.4% |
| FY 2024 | 10-K | $3.0B | $637.8M | 27.9% |
| FY 2023 | 10-K | $3.0B | $642.2M | 27.7% |
| FY 2022 | 10-K | $3.0B | $707.8M | 29.4% |
| FY 2021 | 10-K | $2.8B | $692.8M | 29.5% |
| FY 2020 | 10-K | $2.4B | — | 27.3% |
| Institution | Shares | Value | Reported |
|---|---|---|---|
| BlackRock | 8,484,939 | $3.2B | 2026-06-30 |
| MASSACHUSETTS FINANCIAL SERVICES | 4,625,035 | $2.5B | 2026-06-30 |
| VANGUARD CAPITAL MANAGEMENT | 6,415,552 | $2.4B | 2026-06-30 |
| VANGUARD PORTFOLIO MANAGEMENT | 4,740,524 | $1.8B | 2026-06-30 |
| STATE STREET | 4,382,008 | $1.6B | 2026-06-30 |
| T. Rowe Price Investment Management | 3,817,779 | $1.4B | 2026-06-30 |
| Invesco Ltd. | 3,494,267 | $1.3B | 2026-06-30 |
| GEODE CAPITAL MANAGEMENT | 2,636,146 | $984.8M | 2026-06-30 |
| Fundsmith LLP | 2,273,632 | $852.7M | 2026-06-30 |
| PRICE T ROWE ASSOCIATES | 2,177,958 | $816.8M | 2026-06-30 |
13F Pro Quality Score
Rank #853 of 2,960 stocksTOP 50%
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
AI-extracted from the 10-Q filed 2026-08-11 — Q2 FY2026 (quarter ended July 4, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.
Revenue more than doubled to $1,645M (+113% YoY) on the $13B BDS Business acquisition, but purchased intangibles amortization, inventory step-up and integration costs pushed the company to an operating loss of $86M versus $188M of operating income a year ago.
Broad-based growth led by higher demand for Acquity and Xevo TQ-S instrument systems and double-digit chemistry consumables growth
Includes $72M from the recast Waters Clinical business; remainder is BDS Business revenue since the February 9, 2026 acquisition close
AI-extracted and verified against SEC EDGAR filing text. Not investment advice.